Terson Syndrome: A Comprehensive Clinical Guide

1. Comprehensive Introduction & Overview

Terson syndrome is defined as the occurrence of intraocular hemorrhage in association with intracranial hemorrhage (ICH), most commonly subarachnoid hemorrhage (SAH). First described by Moritz Litten in 1881 and later by Albert Terson in 1900, this clinical entity represents a critical intersection between neurosurgery and ophthalmology.

The syndrome is not merely an ophthalmic finding; it serves as a significant prognostic marker for neurological outcomes. The presence of Terson syndrome often indicates increased intracranial pressure (ICP) and is frequently associated with higher mortality rates in patients suffering from aneurysmal subarachnoid hemorrhage. Clinically, it is characterized by vitreous, subhyaloid, or intraretinal hemorrhage resulting from the rapid elevation of intracranial pressure transmitted through the optic nerve sheath.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanism of Action

The pathophysiology of Terson syndrome is rooted in the anatomical continuity between the intracranial subarachnoid space and the subarachnoid space surrounding the optic nerve.

• The ICP Spike Hypothesis: A sudden, catastrophic rise in intracranial pressure—typically due to the rupture of an intracranial aneurysm—leads to a rapid transmission of pressure along the optic nerve sheath.
• Venous Obstruction: This sudden pressure spike causes acute obstruction of the central retinal vein. The resulting venous stasis leads to the rupture of retinal capillaries or venules.
• The Role of the Internal Limiting Membrane (ILM): The blood often dissects into the subhyaloid space (between the posterior hyaloid face of the vitreous and the internal limiting membrane) or directly into the vitreous body.

Anatomical Pathway

1. Hemorrhage: Rupture of an intracranial aneurysm (most commonly the anterior communicating artery).
2. Pressure Transmission: CSF pressure spikes to match arterial pressure.
3. Sheath Distension: The optic nerve sheath acts as a conduit.
4. Ocular Hemorrhage: Venous congestion leads to retinal and vitreous bleeding.

3. Clinical Staging and Grading

To standardize communication between neurosurgeons and ophthalmologists, several grading systems have been proposed. The most widely accepted is the Hooper-Kaufman Scale, which categorizes the severity of the ocular involvement.

The Hooper-Kaufman Classification

• Grade 1: Small intraretinal or preretinal hemorrhages.
• Grade 2: Larger preretinal hemorrhages (subhyaloid) covering < 50% of the macula.
• Grade 3: Large preretinal hemorrhages covering > 50% of the macula.
• Grade 4: Vitreous hemorrhage (VH) obscuring the optic disc or obscuring the view of the fundus.

4. Clinical Indications and Diagnostic Protocols

Standard Presentation

Patients with Terson syndrome are often comatose or severely neurologically impaired due to the primary intracranial event. In conscious patients, symptoms include:
* Sudden painless loss of vision.
* "Floaters" or dark spots in the visual field.
* Blurred vision (if the hemorrhage is mild).

Key Diagnostic Tests

1. Indirect Ophthalmoscopy: The gold standard for initial examination.
2. B-Scan Ultrasonography: Essential if the vitreous hemorrhage is too dense to permit a view of the retina; it helps identify retinal detachment or vitreous organization.
3. Optical Coherence Tomography (OCT): Used once the hemorrhage clears to assess macular integrity and exclude epiretinal membrane formation.
4. CT/MRI Brain: To confirm the underlying intracranial pathology (SAH, subdural hematoma, or traumatic brain injury).

Differential Diagnosis

It is imperative to distinguish Terson syndrome from other causes of fundus hemorrhage:
* Valsalva Retinopathy: Caused by sudden increase in intrathoracic/intra-abdominal pressure (e.g., heavy lifting, vomiting).
* Diabetic Retinopathy: Generally shows signs of proliferative disease (neovascularization).
* Terson-like Hemorrhage in TBI: Trauma-related hemorrhage without an aneurysm.
* Leukemic Retinopathy: Usually associated with systemic blood dyscrasias.

5. Risks, Side Effects, and Surgical Management

Management Philosophy

Management is typically expectant. In many cases, mild to moderate vitreous hemorrhages clear spontaneously over several months as the blood is resorbed.

When to Intervene (Vitrectomy)

Surgical intervention via Pars Plana Vitrectomy (PPV) is indicated if:
* The hemorrhage is non-clearing after 3–6 months.
* There is risk of amblyopia in pediatric patients (who require rapid visual axis clearance).
* Bilateral dense vitreous hemorrhage exists, impeding the patient's ability to participate in neurological rehabilitation.

Potential Risks of Intervention

• Iatrogenic Retinal Detachment: Due to the difficulty of separating the posterior hyaloid face.
• Endophthalmitis: Rare but severe post-surgical infection.
• Cataract Formation: Acceleration of nuclear sclerosis following vitrectomy.
• Re-bleeding: If the intracranial pressure remains unstable.

6. Long-Term Prognosis

The prognosis for Terson syndrome is twofold: visual and neurological.

1. Neurological Prognosis: Terson syndrome is an independent predictor of poor outcome in SAH. The presence of ocular blood often correlates with a Hunt and Hess Grade of 3 or higher.
2. Visual Prognosis: With proper management, the visual outcome is generally favorable. However, patients may experience long-term complications such as:
   • Epiretinal membranes.
   • Macular holes.
   • Persistent vitreous opacities.

7. Massive FAQ Section

Q1: Is Terson syndrome always bilateral?
A: No, it can be unilateral or bilateral. Bilateral involvement is often associated with more severe intracranial hemorrhage.

Q2: Does the presence of Terson syndrome mean the patient will go blind?
A: Not necessarily. While it causes temporary vision loss, many cases resolve spontaneously. Permanent blindness is rare unless there is associated optic nerve atrophy or severe macular damage.

Q3: How long does it take for the blood to clear on its own?
A: Spontaneous clearance can take anywhere from a few weeks to several months.

Q4: Can children develop Terson syndrome?
A: Yes, it has been documented in pediatric cases, often following severe non-accidental trauma (shaken baby syndrome) or ruptured intracranial aneurysms.

Q5: Is there a preventative medication for Terson syndrome?
A: There is no specific drug to prevent Terson syndrome; the primary focus is the immediate stabilization of the intracranial pressure and the underlying neurosurgical event.

Q6: What is the most common intracranial cause?
A: Ruptured aneurysmal subarachnoid hemorrhage (aSAH) is the most frequent cause, accounting for the majority of cases.

Q7: Can a CT scan diagnose Terson syndrome?
A: A CT scan can show the intracranial hemorrhage, but it is not sensitive enough to detect subtle retinal or vitreous hemorrhages. A dilated fundus exam is required.

Q8: Does the severity of the eye hemorrhage correlate with the severity of the brain injury?
A: Generally, yes. Larger, more dense hemorrhages in the eye are statistically associated with more severe neurological damage and higher mortality rates.

Q9: What is the role of the "Posterior Hyaloid Face" in this syndrome?
A: It acts as a mechanical barrier. The blood typically pools between the retina and this face, preventing immediate mixing with the vitreous gel, which explains why some patients have "subhyaloid" hemorrhages that look like a boat (boat-shaped hemorrhage).

Q10: Are there any contraindications to surgery?
A: Surgery is contraindicated if the patient is medically unstable or if the intracranial pressure is not yet controlled. The patient must be able to tolerate anesthesia and the prone positioning often required post-vitrectomy.

8. Clinical Summary Table: Terson Syndrome

9. Expert Conclusion for Clinicians

Terson syndrome requires a high index of clinical suspicion. In any patient presenting with a significant intracranial event, particularly a ruptured aneurysm, an ophthalmological consultation should be considered a standard of care. By identifying and documenting the presence of Terson syndrome, the medical team gains critical insights into the severity of the intracranial pressure spike, which aids in triaging care and managing patient expectations regarding both neurological recovery and visual rehabilitation.

While the ocular component is secondary to the life-threatening intracranial pathology, the long-term quality of life for the patient is significantly impacted by the visual morbidity. Therefore, a multidisciplinary approach—integrating neurosurgery, critical care, and vitreoretinal surgery—is the cornerstone of successful management for patients afflicted with this complex syndrome.